Institutional Investor Files to Sell Over $2 Million in Protara Therapeutics Stock

summarizeSummary

An institutional investor, 667, L.P., affiliated with Baker Brothers Life Sciences, L.P., has filed a Form 144 indicating intent to sell 26,755 shares of Protara Therapeutics common stock, part of a larger combined sale totaling 348,794 shares.

check_boxKey Events

• Intent to Sell Shares

  667, L.P., an institutional investor and former affiliate, filed a Form 144 to sell 26,755 shares of common stock, valued at approximately $161,584.

• Coordinated Institutional Sale

  This sale is part of a larger, coordinated disposition by Baker Brothers entities, totaling 348,794 shares with an estimated aggregate market value exceeding $2 million.

• Acquired in Public Offering

  The shares were acquired in an underwritten public offering on December 8, 2025.

auto_awesomeAnalysis

This Form 144 indicates that 667, L.P., an entity affiliated with Baker Brothers Life Sciences, L.P., intends to sell 26,755 shares of Protara Therapeutics common stock, valued at approximately $161,584. This sale is part of a larger, coordinated disposition by Baker Brothers entities, which collectively intend to sell 348,794 shares with an estimated aggregate market value exceeding $2 million. While the individual filing is modest, the combined sale by a significant institutional investor and former affiliate suggests a reduction in their stake, which could be perceived negatively by the market. Investors should monitor the actual execution of these sales and any further disclosures from Baker Brothers.